loader

biib

LATEST ARTICLES
Life Science Investing

LEQEMBI® IQLIK Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025"

Life Science Investing

LEQEMBI® IQLIK Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025"

Life Science Investing

Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease

Life Science Investing

"LEQEMBI®" IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in China

Life Science Investing

LEQEMBI® Approved for the Treatment of Alzheimer's Disease in Australia

Life Science Investing

Biogen Provides Regulatory Update on High Dose Regimen of Nusinersen

Life Science Investing

Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates

Life Science Investing

Biogen Receives European Commission Approval for ZURZUVAE® , the First and Only Treatment Approved for Women with Postpartum Depression in Europe

Life Science Investing

Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status

Latest News

More News

Outlook Reports

Resource
Tech
Life Science

Browse Companies

Resource
Tech
Life Science
MARKETS
COMMODITIES
CURRENCIES